Core Viewpoint - Precigen, Inc. announces the publication of a consensus paper recommending PAPZIMEOS as the new standard of care for adults with recurrent respiratory papillomatosis (RRP), marking a significant shift from surgical interventions to a treatment addressing the underlying HPV infection [1][2][5]. Group 1: Treatment Recommendations - The consensus paper, authored by 16 leading physicians, positions PAPZIMEOS (zopapogene imadenovec) as the preferred first-line treatment for adults with RRP, based on clinical experience and literature review [2][4]. - The paper emphasizes a treatment algorithm prioritizing early therapy and a multidisciplinary approach, moving away from repeated surgeries that carry cumulative risks [4][5]. Group 2: Significance of the Consensus Paper - This publication represents a landmark moment for the RRP community, providing clear, evidence-based guidelines for managing a disease that has lacked a defined standard of care for over a century [2][5]. - The recommendations reflect a broad agreement among experts and are developed with input from patients and caregivers, highlighting a commitment to patient-centered care [5][7]. Group 3: About PAPZIMEOS - PAPZIMEOS is the first and only FDA-approved HPV-specific immunotherapy for RRP, designed to generate an immune response against HPV types 6 and 11 [9][10]. - The therapy is based on Precigen's proprietary AdenoVerse platform and represents a new therapeutic paradigm for managing RRP [9]. Group 4: Impact of RRP - RRP is a rare and debilitating disease caused by chronic HPV infection, leading to severe voice disturbances and potential transformation to malignant cancer [7][8]. - The management of RRP has historically involved repeated surgeries, which do not address the underlying cause and can lead to significant morbidity and healthcare burden [8].